Gala­pa­gos plans to hand over Jy­s­e­le­ca and 400 em­ploy­ees to Al­fasig­ma, re­duce work­force by 100

Last year
People
Deals

Am­gen dis­con­tin­ues prostate can­cer drug in $650M write­down, as obe­si­ty pipeline comes in­to fo­cus in 2024

Last year
Pharma

Lil­ly makes an­oth­er move for Verve's ge­net­ic med­i­cines, this time buy­ing Beam's opt-in rights

Last year
Deals
Pharma

Aq­tu­al rais­es $16M for liq­uid biop­sy test for rheuma­toid arthri­tis based on cell-free DNA plat­form

Last year
Financing

Sarep­ta's con­fir­ma­to­ry Duchenne tri­al fails to meet end­point, com­pli­cat­ing fu­ture for con­tro­ver­sial drug

Last year
R&D
Cell/Gene Tx

Biden signs sweep­ing ex­ec­u­tive or­der on AI, with changes com­ing for FDA and health­care

Last year
AI
FDA+

Oph­thalmic drugs face FDA is­sues again, one man­u­fac­tur­er re­spon­si­ble for 26 con­t­a­m­i­nat­ed prod­ucts

Last year
FDA+
Manufacturing

Pfiz­er clos­es sites in New Jer­sey, North Car­oli­na as it ex­e­cutes plan for $3.5B in cost cuts

Last year
Pharma
Manufacturing

WuXi AppTec slash­es 2023 growth rev­enue fore­cast in half due to drop in de­mand for ear­ly-stage ser­vices

Last year
Manufacturing

Fer­til­i­ty ben­e­fits com­pa­ny Prog­y­ny shares how it han­dles start­up val­u­a­tions when look­ing for deals

Last year
Health Tech

Boehringer In­gel­heim pledges ‘Life for­ward’ with new cor­po­rate brand­ing

Last year
Pharma
Marketing

Sen­ate De­moc­rats urge Biden ad­min­is­tra­tion to re­quire in­sur­ers to cov­er OTC birth con­trol

Last year
Pharma
FDA+

No­var­tis strikes a $103M deal for blue­bird's PRV — if it wins one

Last year
Pharma
FDA+

New PBM coali­tion launch­es a Wash­ing­ton, DC-tar­get­ed ad cam­paign to push for leg­isla­tive re­forms

Last year
Pharma
Marketing

Mer­ck to boost Gar­dasil pro­duc­tion; In­creased de­mand for Sanofi’s RSV drug; Take­da ad­dress­es fa­cil­i­ty ...

Last year
Manufacturing

De­ci­phera says its drug for rare joint tu­mor suc­ceed­ed in a PhI­II study, will sub­mit to FDA

Last year
R&D

Vyne aims to raise $88M; Sanofi in­vests in gene ther­a­py com­pa­ny; 4DMT ad­dress­es clin­i­cal hold

Last year
News Briefing

Virid­i­an inks $185M fi­nanc­ing, hires three Ma­gen­ta ex­ec­u­tives as CEO Scott My­ers ex­its

Last year
People

Lex­eo Ther­a­peu­tics pen­cils in $113M IPO for car­diac and Alzheimer's gene ther­a­py read­outs in 2024

Last year
Financing
Startups

Post-pan­dem­ic and flush with cash, Vir eyes new fron­tiers in on­col­o­gy and neu­rol­o­gy

Last year
R&D

Mer­ck KGaA pays $169M up­front in deal for Hen­grui’s PARP1 in­hibitor and ADC

Last year
Deals
R&D

Ex­clu­sive: Trail­ing Karuna, Map­Light Ther­a­peu­tics aims to im­prove schiz­o­phre­nia, CNS drugs with $225M Se­ries C

Last year
Financing
Startups

FDA green­lights first made-in-Chi­na PD-1 as Jun­shi, Co­herus beat BeiGene to the punch

Last year
China
FDA+

No­var­tis plans for po­ten­tial ac­cel­er­at­ed ap­proval for kid­ney dis­ease drug af­ter PhI­II in­ter­im analy­sis re­sult

Last year
R&D
First page Previous page 254255256257258259260 Next page Last page
A service from the Financial Times